Twenty-five years ago the first small molecule inhibitors of Hsp90 were identified. In the
intervening years there has been dramatic progress in basic scientific understanding of the …

Histone deacetylase (HDAC) enzymatic activity has been linked to the transcription of DNA
in cancers including multiple myeloma (MM). Therefore, HDAC inhibitors used alone and in …

Despite tangible progress in recent years, substantial therapeutic challenges remain in
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …

Background Elotuzumab, an immunostimulatory monoclonal antibody targeting signalling
lymphocytic activation molecule (SLAM) family member 7 (SLAMF7), selectively kills …

Purpose Novel agents have improved patient outcome in relapsed or relapsed/refractory
multiple myeloma (MM). Preclinical data show that the novel signal transduction modulator …

The development of resistance to therapy is unavoidable in the history of multiple myeloma
patients. Therefore, the study of its characteristics and mechanisms is critical in the search …

CK2 is a pivotal pro-survival protein kinase in multiple myeloma that may likely impinge on
bortezomib-regulated cellular pathways. In the present study, we investigated CK2 …

Proteasome inhibition has a validated role in cancer therapy since the successful
introduction of bortezomib for the treatment of multiple myeloma (MM) and mantle cell …

Inhibition of histone deacetylase (HDAC) is a promising mechanism for novel, anti‐myeloma
agents. We investigated the effects of the novel HDAC inhibitor resminostat on multiple …

Histone acetyltransferases and histone deacetylases (HDACs) are multifunctional enzymes
that posttranslationally modify both histone and nonhistone acetylation sites, affecting a …